- The American Diabetes Association held its Scientific Sessions in Chicago on June 25, 2025.
- Novo Nordisk presented data at the American Diabetes Association Scientific Sessions held in Chicago.
Novo Nordisk presented STEP UP trial data at the ADA Scientific Sessions in Chicago, seeking approval for a new oral formulation.
1 report, 0 independent
Updated Jun 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novo Nordisk presented STEP UP trial data at the ADA Scientific Sessions in Chicago, seeking approval for a new oral formulation.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
-
American Diabetes Association
U.S.-based nonprofit organization
Related events
- KAIMRC signed clinical-trial capability partnership with Novo Nordisk and an AI research partnership with Rutgers University.
- Novo Nordisk launched insulin in the US market.
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
- Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.
- The FDA has granted market exclusivity for certain drugs, while analysts are comparing Novo Nordisk's development phase to AI rollouts, amidst concerns over patent cliffs.
Coverage
Newest first; wire copies grouped- Unknown outlet